Overview
Hemas is a diversified Sri Lankan group spanning healthcare, consumer brands, mobility, leisure, travel, aviation and logistics. The latest quarter showed stronger sales and operating profit but weaker profit after finance costs and other below-the-line items, making funding discipline more important than the headline revenue recovery.
The group has also completed a 75% acquisition of Kenya's Twiga Stationers and Printers, reported on 18 August 2026. The disclosed US$16.2 million consideration establishes an East African consumer platform, but the available announcement gives no Twiga revenue or profit figure with which to judge its earnings contribution.
Price performance
At LKR 32.80 on 16 November 2026, the share had gained 4.5% over three months against a 0.5% ASPI gain. It sat around the middle of its 52-week range, while 60-day volatility was below its own one-year norm and recent trading volume was higher than its 60-day average.
The three-year record includes two falls of 15% or more; the deepest was 24% and took seven months to recover. A LKR 1 million order is about 19% of what trades on a typical day, a noticeable part of a day's trading, so liquidity is adequate for modest dealing but not deep by large-order standards.
Valuation
At 11.4 times earnings, the price represents LKR 11.40 for every LKR 1 of trailing profit, below the diversified-holdings median of 14.0 times and at the 29th percentile among peers with P/E data. Its 1.71 times P/B means paying LKR 1.71 for each LKR 1 of net assets, above the sector median of 1.17 times and at the 70th percentile; the latest audited ROE of 15.7% helps explain why book value commands a premium.
The 3.8% trailing dividend yield exceeds the sector median, while dividends rose from LKR 0.90 in FY2025 to LKR 1.00 in FY2026. The current FY2027 LKR 0.25 first interim payment is incomplete as a full-year payout measure.
The own-history signals differ: P/B is more expensive than 76% of days since January 2019, while P/E is cheaper than 57% of days over that period. A buyer at this price is relying on a latest quarter that supplied 23.4% of trailing EPS; had that quarter achieved its year-ago net margin, the same price would equal 10.9 times earnings. Market-wide, Hemas scores 70 of 100 on price against book value, earnings and dividends, placing it in the moderately undervalued band.
News and sentiment
Direct coverage was about normal, with five articles in the past 30 days. The 90-day material-news balance was mixed, with 10 negative articles against eight positive, largely reflecting the contrast between revenue growth and pressure from finance costs and margins.
Results reported on 6 November confirmed strong September-quarter sales and a profit decline. The same reporting highlighted the completed Twiga acquisition, while no earnings terms for the acquired business were disclosed. The LKR 0.25 first interim dividend went ex on 16 November 2026 and is payable on 4 December 2026.
Financials
September-quarter revenue rose 17.1% year-on-year to LKR 37.8 billion and operating profit increased 8.1% to LKR 3.8 billion, but net profit slipped 1.7% to LKR 2.1 billion. The difference matters because the operating businesses produced more profit, yet finance costs, tax and other below-the-line items absorbed LKR 1.7 billion, up from LKR 1.3 billion a year earlier.
Gross margin was 29.7% versus 32.8% a year ago, operating margin was 10.0% versus 10.8%, and net margin was 5.6% versus 6.7%. Against past September quarters on the same group basis, gross margin was middling at fifth of eight, operating margin fourth of eight, and net margin third of eight. The profit result is therefore softer year-on-year but not weak against its own comparable September record.
The twelve months to September 2026 generated LKR 133.1 billion of revenue, up 7.0%. Equity attributable to owners was LKR 57.6 billion at September, and the share count was unchanged at 3.0 billion from the latest balance-sheet count, so the reported per-share figures are not being mechanically altered by a new share issue.
Risks
The leading risk is a rise in working-capital funding and finance costs following the annual balance-sheet date. Total debt was LKR 18.4 billion at September against LKR 13.3 billion of cash, while quarterly finance cost reached LKR 464 million. That funding burden was a key reason a growing operating profit did not translate into growing net profit.
The last audited position was stronger: gearing, meaning debt against owners' equity, was 10.8%; interest cover, meaning operating profit divided by the interest bill, was 13.79 times; and the current ratio was 1.72. Those measures describe March rather than the later acquisition and working-capital position, so they do not remove the importance of the September debt increase.
Cash conversion at the last annual filing was 0.83 times, meaning not every rupee of operating profit arrived as operating cash. Healthcare accounts for 62% of reported segment revenue, while consumer retail accounts for 38%; the market backdrop as at 16 November 2026 includes rupee weakness and higher fuel prices, conditions that can add input and distribution pressure across those operations.
Outlook
As at 16 November 2026, the next scheduled information event is the December 2026 interim-quarter filing, expected between 6 and 14 February 2027. It should clarify whether the strong September sales conversion persists, whether Twiga is contributing to the group, and whether working-capital borrowing and finance costs remain elevated.
The available data cannot yet isolate Twiga's revenue, margin or financing effect. The already ex-dividend payment on 4 December 2026 is a cash distribution to prior holders, and a buyer after the 16 November ex-date does not receive it.